BioXcel Therapeutics Announces FDA Approval of IGALMI

Long

BioXcel Therapeutics, Inc. (NASDAQ:BTAI)

NASDAQ:BTAI BioXcel Therapeutics, Inc.

beyondta

BTAI: BioXcel Therapeutics
2022-04-06 07:00:00
BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.